ISR

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Retrieved on: 
星期一, 三月 11, 2024

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance.
  • This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.
  • Izokibep was well-tolerated with a favorable safety profile consistent with previous experience and the IL-17A class, without evidence of the safety liabilities observed with targeting IL-17A&F.
  • This reinforces our enthusiasm for developing izokibep as an important potential new medicine for patients.”

Billion Dollar Uranium Market Growing at a Solid Rate Along With Rising Adoption Strategies

Retrieved on: 
星期三, 三月 6, 2024

A report from Market Reports World said that the global Uranium market size is expected to expand at a CAGR of 3.6% of 3.6% during the forecast period, reaching USD $3.27 Billion by 2027.

Key Points: 
  • A report from Market Reports World said that the global Uranium market size is expected to expand at a CAGR of 3.6% of 3.6% during the forecast period, reaching USD $3.27 Billion by 2027.
  • Another report from 360Research Reports said: “The Global Uranium Mining, market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031.
  • The high adoption of advanced technology and the presence of large players in this region are likely to create ample growth opportunities for the market.
  • Europe also play important roles in global market, with a magnificent growth in CAGR During the Forecast period 2024-2031.

Demand Booming as Global Uranium Mining Market Expected To Reach $11.3 Billion By 2030

Retrieved on: 
星期三, 二月 21, 2024

It also said that the global uranium mining market is expected to reach US$ 11,388.3 million by 2030, with an annual growth rate of more than 5.0%.

Key Points: 
  • It also said that the global uranium mining market is expected to reach US$ 11,388.3 million by 2030, with an annual growth rate of more than 5.0%.
  • The uranium mining market is estimated to be 53.0 thousand tons (kt) in 2023.
  • The report added: “Uranium mining is the extraction of uranium ore from the ground for use in nuclear power plants and the development of nuclear weapons.
  • Based on the mining method, the open-pit mining segment is the most common method of uranium mining, accounting for over 90% of global uranium production in 2022.

Bridger Aerospace Announces Earliest Fire Season Dispatch in Company History

Retrieved on: 
星期二, 二月 20, 2024

BELGRADE, Mont., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced the deployment of a Pilatus PC-12 Multi-Mission Aircraft (MMA) to Oklahoma to provide aerial intelligence for early-season wildfires.

Key Points: 
  • BELGRADE, Mont., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced the deployment of a Pilatus PC-12 Multi-Mission Aircraft (MMA) to Oklahoma to provide aerial intelligence for early-season wildfires.
  • This marks the earliest seasonal deployment of any Bridger Aircraft since the company’s inception in 2014.
  • Bridger Aerospace operates two Multi-Mission Aircraft under a 5-year contract with the Department of the Interior (DOI) and Bureau of Indian Affairs (BIA), initiated during the 2023 fire season to leverage the architecture of Bridger’s proprietary data platform and leading-edge sensor and mapping capabilities.
  • Tim Sheehy, Chief Executive Officer of the Company, commented, “Team Bridger is always ready to respond when called upon to protect our communities.

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

Retrieved on: 
星期三, 三月 6, 2024

Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.

Key Points: 
  • Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.
  • Participants received comprehensive and incentivised adherence support while taking guideline-recommended, three-drug regimen oral ART, including dolutegravir and bictegravir-based regimens, to achieve viral suppression.
  • 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC {difference -14.4 (98.75% CI–29.8%, -0.8%)}.
  • Three participants in the LA-ART arm had serious injection site reactions (ISR) and one participant discontinued due to an ISR.

ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses

Retrieved on: 
星期一, 三月 4, 2024

ViiV Healthcare is conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.

Key Points: 
  • ViiV Healthcare is conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.
  • Future areas of study will include its potential use in combination with other medicines as a complete, ultra long-acting HIV treatment regimen.
  • ViiV Healthcare is a pioneer and leader in the development of long-acting HIV medicine, having already brought innovations through injectable therapies to the HIV community.
  • Based on these combined findings, ViiV Healthcare is no longer pursuing CAB 200 SC + rHuPH20 for ultra long-acting dosing.

World View Secures Strategic Series D Funding Led by SNC

Retrieved on: 
星期二, 二月 27, 2024

World View, a global leader in stratospheric exploration and flight, announces the successful opening and initial funding of a Series D round.

Key Points: 
  • World View, a global leader in stratospheric exploration and flight, announces the successful opening and initial funding of a Series D round.
  • (Photo: Business Wire)
    This strategic investment builds upon the multi-year strategic partnership initiated in 2022 between World View and SNC.
  • As part of the Series D funding round, two notable individuals join the World View Board of Directors.
  • “SNC is committed to quality and excellence in performance, and we look forward to enhancing this much-needed capability in coordination with World View."

Skydio Begins Delivery of X10D Small UAS to Defense Customers; Debuts Dynamic Channel Switching

Retrieved on: 
星期二, 二月 27, 2024

Skydio also announced dynamic channel switching to monitor signal interference and move to a clearer channel to improve wireless transmission signal quality during flight, ensuring troops maintain communication with the drone to accomplish their mission.

Key Points: 
  • Skydio also announced dynamic channel switching to monitor signal interference and move to a clearer channel to improve wireless transmission signal quality during flight, ensuring troops maintain communication with the drone to accomplish their mission.
  • Skydio also plans to offer dynamic channel switching soon to customers already using the X10.
  • “The arrival of X10D to customers is truly a milestone moment for Skydio and the allied defense and government community,” said Mark Valentine, President of Global Government at Skydio.
  • To learn more about the future of defense technology with Skydio X10D, please visit: skydio.com/x10d

Umbra Unveils Bistatic SAR Data from its Tandem Pair of Satellites

Retrieved on: 
星期四, 三月 7, 2024

WASHINGTON, March 7, 2024 /PRNewswire/ -- Umbra, a vertically integrated space technology company, proudly announces the forthcoming release of imagery from its tandem pair of Synthetic Aperture Radar (SAR) satellites.

Key Points: 
  • WASHINGTON, March 7, 2024 /PRNewswire/ -- Umbra, a vertically integrated space technology company, proudly announces the forthcoming release of imagery from its tandem pair of Synthetic Aperture Radar (SAR) satellites.
  • Umbra is set to provide customers with bistatic SAR data later in 2024.
  • Umbra, a SAR satellite provider, is set to provide customers with bistatic data in 2024.
  • Umbra's high-performance SAR satellites deliver the highest quality SAR data at unprecedented volumes and area density, enabling the US.

Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon

Retrieved on: 
星期五, 三月 1, 2024

MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

Key Points: 
  • First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence
    MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
  • ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9029352-boston-scientific-fda-ap...
    "With more than 100,000 patients treated globally to date in both clinical and commercial settings, we are very pleased to introduce this proven therapy as the first drug-coated coronary balloon in the U.S," said Lance Bates, president, Interventional Cardiology Therapies, Boston Scientific.
  • Boston Scientific plans to launch the technology in the U.S. in the coming months.